American Psychiatric Association (2007). American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. 2nd edn. Available at: http://www.psych.org (last accessed 11 November 2008).
Australian Pharmaceutical Advisory Council (2002). Guidelines for Medication Management in Residential Aged Care Facilities. 3rd edn. Canberra: Commonwealth of Australia.
Australian Senate (1995). Psychotherapeutic Medication in Australia: Report of the Senate Community Affairs References Committee. Canberra: Australian Government Printing Service.
Avorn, J. et al. (1992). A randomised trial of a program to reduce the use of psychoactive drugs in nursing homes. New England Journal of Medicine, 327, 168–173
Ballard, C., Waite, J. and Birks, J. (2006). Atypical antipyschotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews, 1, CD003476.
Ballard, C. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long -term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151–157.
Conn, D. and Madan, R. (2006). Use of sleep-promoting medications in nursing home residents. Drugs and Aging, 23, 271–287.
Crotty, M. et al. (2004). An outreach intervention to implement evidence based practice in residential care: a randomised controlled trial. BMC Health Services Research, 4, 6.
Draper, B. et al. (2001). Use of psychotropics in Sydney nursing homes: associations with depression, psychosis, and behavioral disturbances. International Psychogeriatrics, 13, 107–120.
Fonad, E., Robins Wahlin, T., Winblad, R., Emami, A. and Sandmark, H. (2008). Falls and fall risk among nursing home residents. Journal of Clinical Nursing, 17, 126–134.
Madhusoodanan, S. and Bogunovic, O. (2004). Safety of benzodiazepines in the geriatric population. Expert Opinion Patient Safety, 3, 485–493.
Monette, J. et al. (2008). Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry, 23, 574–579.
Nishtala, P., McLachlan, A., Bell, J. and Chen, T. (2008). Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. American Journal of Geriatric Psychiatry, 16, 621–632.
Ray, W., Blazer, D., Schaffner, W. and Federspiel, C. (1987). Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. American Journal of Public Health, 77, 1448–1450.
Roberts, M. et al. (2001). Outcomes of a randomised controlled trial of a clinical pharmacy intervention in 52 nursing homes. British Journal of Clinical Pharmacology, 51, 257–265.
Royal Australian College of General Practitioners (2005). Medical care of older persons in residential aged care facilities. Silver Book National Taskforce, 4th edn. Available at http://www.racgp.org.au/silverbookonline (last accessed 8 September 2009).
Schmidt, I., Claesson, C., Westerholm, B., Nilsson, L. and Svarstad, B. (1998). The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. Journal of the American Geriatrics Society, 46, 77–82.
Schneider, L., Dagerman, M. and Insel, P. (2006). Efficacy and Adverse effects of atypical Antipsychotics for dementia: Meta-analysis of randomised, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191–210.
Snowdon, J., Day, S. and Baker, W. (2005). Current use of psychotropic medication in nursing homes. International Psychogeriatrics, 17, 1–10.
Westbury, J., Jackson, S. and Peterson, G. (2009). Psycholeptic use in Tasmanian aged care homes. International Journal of Clinical Pharmacy and Therapeutics. In press.
Woodward, M. (2006). Hypnosedatives and the elderly – are we doing enough to reduce risk and improve outcomes? Journal of Pharmacy Practice and Research, 36, 5.